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Studies reveal that 10-27% of older adults chronically use anticholinergic medications.
Increased cumulative anticholinergic burden scores are associated with increased risks of
dementia. The mechanisms by which anticholinergic drugs negatively impact cognition remain
elusive.

However, researchers speculate that the drug’s impairment of cholinergic neurons

promotes neuroinflammation.
Research question or Hypothesis
We hypothesize that drugs with anticholinergic properties will induce inflammation in the brain.
MCP1 and IL 6 are chemokines that contribute to neuroinflammation. We investigated the
influence of diphenhydramine (Benadryl) on the production of MCP1 and IL-6 in Normal Human
Astrocytes and Paroxetine on the production of MCP1 in Normal Human Astrocytes and Normal
Human Brain Microvascular Endothelial Cells.
Methods
Normal Human Astrocytes were cultured (seeded at 5,000 cells/cm2) and treated with a
clinically relevant concentration (equivalent to clinically observed Cmax for the respective drugs)
of diphenhydramine (66ng/ml) and Paroxetine (1.67*10-4
 mM). R
 NA was isolated and converted
into cDNA, and then gene expression was measured via RT-PCR. MCP1 and IL-6 protein
production were measured from cell culture supernatants by ELISA. One-way ANOVA
compared MCP-1 and IL-6 protein concentrations with Tukey correction for multiple corrections.
The gene expression was reported with relative significance (p= 0.05) using Student’s t-test.
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Conclusions
Drugs with anticholinergic properties are considered to be pro-inflammatory. However, our data
from

normal

human

astrocytes

treated

suggest

that

diphenhydramine

possesses

anti-inflammatory properties. This preliminary finding suggests the possibility of pathological
mechanisms of anticholinergic medications with dementia that may not be associated with
inflammation.
Our data from Paroxetine in normal human brain microvascular endothelial cells suggest that
Paroxetine possesses pro-inflammatory properties. Our preliminary findings indicate the
possibility of a pathological pro-inflammatory mechanism associated with Paroxetine. Further
evaluation of anticholinergic drugs in the human brain is warranted.
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1. INTRODUCTION
In the 20th century, astonishing population growth was aging in the United States. In 1900, 3.1
million Americans were 65 years and older, representing 4% of the total population. According
to the Census Bureau, in 1986, the population had grown to 29.2 million persons or 12.1% of
the total population. The population projections of the 21st century still indicate the continuation
of growth. Those 85 years and older are the most rapidly growing population in terms of actual
numbers and percentages of the total population. Concurring to the Social Security
Administration, the number of individuals at or above age 65 is expected to rise from thirty-four
million in 1995 to eighty-seven million in 2080. Whereas, the population at or above age
eighty-five is expected to grow from 3.8 million in 1995 to 18.3 million in 2080. (Biology of AgingHandbook)
1.1 AGING
Aging is the process of growing older. It is a gradual, continuous, and complex process
associated with dynamic biological, physiological, psychological, and behavioral changes. Even
though aging is associated with mild changes such as graying of hair,

some significant

age-related changes can decline daily-life activities and increase vulnerability to various
diseases, frailty, and disability. Aging is a substantial chance for many acute and chronic
conditions, including neurodegenerative disease. There is no single principle to explain aging.
However, studies have shown that aging can be slowed, suggesting that we can delay the
appearance or reduce the number of diseases and increase older adults’ health span by aiming
for aging. Researchers are presently centering on hereditary, natural life-style, behavioral and
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social components, and their effect on the initiation and progression of age-related diseases and
neurodegenerative conditions. (www.nia.nih.gov)
1.2 COMPLEXITY OF AGING
More than 248 million of roughly 418 million people aged 65 years and over (59%) now reside in
the developing countries. The world’s elderly distribution will be shifting considerably in the
upcoming decades, with a growing proportion of 67% by 2020. Asia has the first noteworthy
number of older adults, 217 million. China alone has 87 million people (6.8 percent of its
populace) aged sixty-five year and older, and this will increment to 167 million (11.5 percent) by
2020.1
With advancing age, there is an increased vulnerability to chronic health problems. New
diagnoses will further add complexity to the health status of older adults with pre-existing health
problems. Many health disorders experienced by older individuals are commonly managed with
medications. Antibiotics, cardiovascular, psychotropics, anticholinergics are used routinely to
treat health disorders observed in older adults. However, drug development clinical trials often
exclude older adults. 2

A survey conducted in Australia, New Zealand, Canada, United

Kingdom, and the United States, showed that approximately 75% of those aged 65 took at least
one prescription drug regularly for chronic medical conditions. 3
Multimorbidity that increases with social deprivation and age is also associated with functional
decline, more reduced quality of life, increased mortality, and significantly more healthcare
usage. Multimorbidity is characterized by two or more chronic conditions that cannot be cured
and are controlled through medications and other treatments. 7
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The prevalence of polypharmacy is also common in this segment of the population.
Polypharmacy defined as prescribing a threshold of five to seven medications or more.
Inappropriate medication use, improper drug use, inappropriate prescribing, potentially
inappropriate prescription are the terms used to recognize under-prescribing, over-prescribing,
and mis-prescribing practices 4 . Multiple cohort studies have recently reported increased,
potentially inappropriate medicines in acute and long-term settings in community-dwelling older
people. Furthermore, these studies revealed associations between inappropriate medications
and increased risks of adverse drug reactions, morbidity, and mortality. 5 The use of multiple
medicines, especially with high anticholinergic properties in older adults, leads to increased
cognitive function risks, impaired judgment, and a decline in intellectual understanding. During
the hospital stay, older adults with cognitive impairment are also at an increased risk of delirium,
resulting in extended hospital stays and increased thirty-day mortality rates. 6
Although drug therapy is considered central in most chronic medical conditions experienced by
older adults, a substantial number of these individuals also experience adverse drug reactions
(ADR). ADRs are a severe health problem, and it is reported that older adults are seven times
more likely than younger adults to have ADRs that require hospitalization. The number of
prescription drugs is the primary indicator of risk for an adverse drug reaction. As the number of
prescriptions increases in older adults, the odds of an adverse drug reaction, especially
cognitive impairment, are increased. 8 Cognitive impairment (CI), in older people, is broadly
definable ADR. Some drugs are associated with increased risks of depression, suicide,
seizures, and confusion. These symptoms are more challenging to assess and can impact the
cognitive abilities of older adults.
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Drugs with anticholinergic properties are prescribed widely to older adults, but adverse effects
often restrict their use. Many commonly used medications, such as digoxin, psychotropics, and
anticholinergic (muscarinic-blocking) properties, have been consistently associated with
increased cognitive impairment risks. Several alterations in intrinsic physiological factors, such
as pharmacokinetics and pharmacodynamics changes, also put older adults at increased
chances of developing cognitive impairment from medications. 2

2. TOOLS TO ASSESS QUALITY OF GERIATRIC CARE
In recent years, several criteria have been developed to classify medication usage’s
appropriateness while protecting older adults from adverse events. The Beer’s criteria,
Screening Tool of Older Persons Prescription (STOPP), and Screening Tools to Alert Doctors
To Right Treatment (START) are the best known and widely studied in the US and Europe. 9
2.1 BEER’S CRITERIA
The American Geriatrics Society (AGS) Beer’s criteria for Potentially Inappropriate Medication
(PIM) Use in Older Adults is utilized broadly by clinicians, educators, researchers, healthcare
administrators, and regulators. The AGS Beers Criteria is a list of potentially inappropriate
medications that should be avoided by older adults in most cases or under specific situations,
such as in certain diseases or conditions. The five types of criteria in the 2019 updated Beers
criteria include:
1. Medications that are potentially inappropriate in most older adults.
2. Those that should typically be avoided in older adults with certain conditions.
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3.

Drugs to use with caution.

4. Drug-drug interactions.
5. Drug dose adjustment based on kidney function.
The Beers criteria are considered for use in adults 65 years and older in all ambulatory, acute,
and traditional care settings, except for the hospice and palliative care settings. To improve
medication selection, educate clinicians and patients, reduce adverse drug events, and serve as
a tool for evaluating the quality of care, cost, and drug use patterns of older adults. The primary
objective of the 2019 update proceeds to be improving the care of older adults by diminishing
their exposure to Potentially Inappropriate Medications (www.americangeriatrics.org).

3. LITERATURE REVIEW
Several investigators have reported the use of anticholinergics associated with sustained
cognitive defects in older adults. A prospective population-based cohort study was conducted to
examine if cumulative anticholinergic use is associated with an increased risk for incident
dementia. The researchers used data from the Adult Changes in Thought study in Group
Health. The study included 3434 participants aged 65 or older with no dementia. The most
anticholinergic classes used were tricyclic antidepressants, first-generation antihistamines, and
bladder antimuscarinics. They observed that during the mean follow-up of 4.8 years, 23.2%
developed dementia, whereas,79.9% considered to have possible Alzheimer’s disease (AD). 10

A longitudinal study was conducted between 2 cohorts (participants taking medium or high
anticholinergic medications compared to those not taking these medications) to determine the
association between anticholinergic medications use and cognition, glucose metabolism and
20

brain atrophy in cognitively healthy older adults from the Alzheimer’s Disease Neuroimaging
Initiative (ADNI) and Indiana Memory and Aging Study (IMAS). They found that medications with
medium or high anticholinergic activity were associated with imperfect memory, brain
hypometabolism, brain atrophy, and increased cognitive impairment risk. This study was the first
to examine the in vivo brain structural and functional differences. 11

Selective Serotonin Reuptake Inhibitors, including Fluoxetine, Paroxetine, Citalopram,
Sertraline, Escitalopram is the most prescribed type of antidepressants. But little is known if
there is a connection between depression and dementia. A prospective cohort study was
conducted in community-dwelling individuals aged 65 years and older adults without dementia,
to

determine

if

antidepressants

(serotonin

reuptake

inhibitor-

Paroxetine,

tricyclic

antidepressants, serotonin antagonist and reuptake inhibitors) use was associated with
increased risks of dementia. The findings concluded that 25% of the participants developed
dementia, whereas 22% developed possible Alzheimer’s disease. Paroxetine was found to be
most associated with increased dementia risk. 12
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4. ANTICHOLINERGICS
A vast number of medications on the updated (2019) Beer’s list are considered potentially
inappropriate due to their anticholinergic properties. Older adults subjected to increased
anticholinergic load due to the extensive use of anticholinergic/antimuscarinic medications and
the medications with anticholinergic side effects (antihistamine, antidepressants, skeletal
muscle relaxant, antipsychotics, antispasmodic). Older adults widely use anticholinergics
medications as an OTC or as a prescription for diverse conditions such as seasonal allergies,
overactive bladder, and depression. The predominance of anticholinergic use in older adults
ranges from 8-37%. 13
 The risks may outweigh the benefits of using anticholinergics in older
adults. Well-known chances of anticholinergic burden are falls, worsened functioning, and
worsened cognition. Older adults are more sensitive to anticholinergic effects due to
pharmacokinetic and pharmacodynamic changes, diminished acetylcholine transmission in the
brain, and increased permeability of the blood-brain barrier. It is suspected that the cognitive
impairment associated with these agents can be reversible on the medications’ discontinuation.
Several investigators have still reported that the anticholinergics can be related to sustained
cognitive defects such as mild cognitive impairment or dementia. 10

4.1 ANTICHOLINERGIC BURDEN LIST
Anticholinergic medications are classified on an anticholinergic burden list. The ACB list has
been previously used to identify cognitive impairment risks in many populations using
anticholinergic drugs. The Anticholinergic Cognitive Burden List identifies anticholinergics with
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varying degrees of anticholinergic activities. Medications on the Anticholinergic Cognitive
Burden list are classified into two groups:
1. Medications with possible anticholinergic effects: those with in-vitro anticholinergic
activity with no reported evidence of clinical anticholinergic properties.
2. Medications with definite anticholinergic activity: those with functional and clinically
relevant effects on cholinergic signaling. 6
It is recommended that clinicians, pharmacists, and healthcare professionals consider the
anticholinergic properties of medications when adding or changing the patient's drug regimen to
minimize the anticholinergic side effects ( Rochon, Paula., 2020)
4.2 MECHANISM OF ACTION OF ANTICHOLINERGICS
Generally, anticholinergics produce their effects by blocking acetylcholine (Ach), which acts as a
neurotransmitter at the presynaptic terminal at the central and peripheral nervous system. They
inhibit the parasympathetic nerve impulses by selectively blocking the binding of acetylcholine to
nerve cells. Apart from producing therapeutic effects, some anticholinergics produce some
therapeutic results that are not primary therapeutic effects. The mechanism by which they
produce these effects is still unknown, but researchers have speculated that the cholinergic
neuron’s direct impairment may underlie these effects. 10
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5. THE CHOLINERGIC ANTI-INFLAMMATORY PATHWAY
The inflammatory reflex is stimulated when the afferent vagus nerve senses the inflammatory
products such as cytokines, damage-associated pathogen patterns through the cytokine
receptor, and pattern recognition receptors. The nerve activity is transfer through the central
nervous system (CNS) to the efferent vagus nerve. The first pathway involves the splenic nerve,
a coordinate association between the afferent vagus nerve and splenic nerve is still debatable.
Triggered splenic nerves release norepinephrine from their terminals, which interacts with
β2-adrenergic receptors, expressed on the choline acetyltransferase (ChAT)-positive T cells
within the spleen, causing the release of acetylcholine (ACh) for specific T cell. Acetylcholine
binds to α7 nicotinic acetylcholine receptors (α7nAChRs) expressed on macrophages, resulting
in suppressing proinflammatory cytokine production by macrophages.14
5.1 HYPOTHESIS
Cholinergic signaling is anti-inflammatory; we are hypothesizing that anticholinergic medications
will induce inflammation in the brain.
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6. SPECIFIC AIMS
1. To

characterize

the

effect

of

Diphenhydramine

on

the

physiological

and

pathophysiological properties of normal human astrocytes.
2. To characterize the effects of Paroxetine on the physiological and pathophysiological
properties on normal human astrocytes.
3. To characterize the effects of Paroxetine on the physiological and pathophysiological
properties on normal human brain microvascular endothelial cells.
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7. DIPHENHYDRAMINE
Diphenhydramine hydrochloride is an antihistamine drug with a chemical name of
2-(diphenylmethane)-N, N -dimethyl ethylamine hydrochloride with a molecular formula C 17H
21NO•HCI (molecular weight 291.82) (www.accessdata.fda.gov)

7.1 PHYSICOCHEMICAL PROPERTIES
It occurs as a white odorless, crystalline powder and soluble in water and alcohol.

7.2 DOSAGE
Adults: 25 to 50 mg, three or four times daily.
The nighttime sleep-aid dosage is 50 mg at bedtime.
7.3 STORAGE
Keep tightly closed—store at 20° to 25°C (68° to 77°F). Protect from freezing and light.
7.4 PHARMACOLOGY OF DIPHENHYDRAMINE
Diphenhydramine hydrochloride is an antihistamine with anticholinergic and sedative effects.
Diphenhydramine (Benadryl) is a first-generation H1 antagonist that acts as a reversible
competitive inhibitor of histamine, which binds to the H1 receptor.
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7.5 USAGE
Diphenhydramine hydrochloride is used to relieve runny nose, itching of the nose or throat, and
itchy, watery eyes from hay fever or upper respiratory allergies, for active and prophylactic
treatment of motion sickness and nighttime sleep aid.
7.6 PHARMACOKINETICS OF DIPHENHYDRAMINE
Diphenhydramine

pharmacokinetics

in

adults

for

single doses of 25 and 50 mg

diphenhydramine HCl have been reported in several studies. Following the intravenous
administration of 50 mg, diphenhydramine is observed at a maximum concentration of 66ng/ml
(concentration used in the experiments to treat the normal human astrocytes and normal human
brain microvascular endothelial cells).

Diphenhydramine’s total systemic clearance is 6.16

mL/min/kg, the volume of distribution is 4.54 L/kg, and its exponential half-life is 8.5 hours.
Following oral administration of 50 mg in studies conducted, diphenhydramine attained
maximum concentrations at 2.3 and 2.2 hours and had exponential half-lives of 9.2 and 9.8
hours. Diphenhydramine undergoes the first-pass metabolism after oral administration with an
absolute bioavailability of 72% ± 8%, with about 2% of the dose remaining unchanged in the
urine. Diphenhydramine is metabolized via demethylation to N-demethyl diphenhydramine,
which is demethylated to N, N-didemethyl diphenhydramine further metabolized by oxidative
deamination to diphenylmethoxyacetic acid. The initial N-demethylation has not been reported
to be related to cytochrome p450 2D6 (CYP2D6) activity. Still, the subsequent N-demethylation
has reduced in subjects who were phenotype as CYP2D6 poor metabolizers. In drug-interaction
pharmacokinetic studies with venlafaxine and metoprolol, diphenhydramine was shown to be an
inhibitor of CYP2D6 15

27

8. NORMAL HUMAN ASTROCYTES
Michael von Lenhossék introduced the term astrocyte (Astron, star, and kytos, a hollow vessel,
later cell, i.e., star-like cell) in 1895. Astroglia belongs to a class of neural cells (also known as
astrocytes) of ectodermal, neuroepithelial origin that maintain homeostasis and provide a
defense of the central nervous system (CNS). Astrocytes are highly diverse in form and function
and exhibit high adaptive plasticity, which helps in functional maintenance of the CNS in
development and aging. Astrocytes are involved in controlling homeostasis of the CNS at all
levels of the organization. Through transporting the significant ions and protons, removing and
catabolizing neurotransmitters, releasing neurotransmitter precursors, and scavengers of
reactive oxygen species, astrocytes maintain the molecular homeostasis. Astrocytes are also
involved in supporting the neurotransmission and controlling cellular homeostasis through
embryonic neurogenesis (that occurs from radial glia) and adult neurogenesis (which includes
stem astrocytes of neurogenic niches). By synthesizing glycogen and supplying neurons with
energy substrates, astrocytes regulate the metabolic homeostasis.16

9. CHEMOKINES (MCP-1) AND CYTOKINE (IL- 6)
Chemokines are small heparin-binding proteins that constitute a large family of peptides
(60–100 amino acids) related to cytokines structurally. The primary function is to regulate cell
trafficking. Chemokines can be classified into four subfamilies based on the number and
location of the cysteine residues at the N-terminus of the molecule and are named CXC, CC,
CX3C, and C. The structure of chemokines is composed of three distinct domains: (1) a highly
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flexible N-terminal domain, which is constrained by disulfide bonding between the N-terminal
cysteine, (2) a long loop that leads into three antiparallel β-pleated sheets; and (3) an α-helix
that overlies the layers. Chemokines are divided into two main functional subfamilies:
inflammatory and homeostatic chemokines. Inflammatory chemokines control the recruitment of
leukocytes in inflammation and tissue injury, whereas, homeostatic chemokines attain
housekeeping functions such as navigating leukocytes to and within secondary lymphoid organs
and the bone marrow and the thymus during hematopoiesis.
Chemokines induce chemotaxis by activating G-protein-coupled receptors (GPCRs), including
adhesion molecules and glycosaminoglycans (GAGs). Chemokines bind to specific cell surface
transmembrane receptors coupled with heterotrimeric G proteins, which leads to the activation
of intracellular signaling cascades, which further causes the migration towards chemokines.
The monocyte chemoattractant protein-1 (MCP-1/CCL2) is a member of the C-C chemokine
family and a potent chemotactic factor for monocytes. Located on chromosome 17 (chr.17,
q11.2), human MCP-1 is composed of 76 amino acids. MCP comprises four members (MCP-1,
−2, −3, and −4). CCL2 is produced by various cell types, either by oxidative stress, cytokines, or
growth factors. CCL2 is produced by many cell types, such as endothelial, fibroblasts, epithelial,
smooth muscle, mesangial, astrocytic, monocytic, and microglial cells. CCL2 regulates
monocytes migration and infiltration, memory T lymphocytes, and natural killer (NK) cells. 18

Cytokines are small proteins, Interleukin-6 (IL-6) is a cytokine which induces the maturation of B
cells into antibody-producing cells. The essential sources of IL-6 in the CNS are neurons,
astrocytes, microglia, and endothelial cells. IL-6 participates in neurogenesis, influencing both
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neurons and glial cells, oligodendrogliogenesis, and astrogliogenesis. IL-6 is a prototypical
four-helix bundle cytokine. 19


10. NEURODEGENERATIVE GENES
Glutamate is the major excitatory neurotransmitter of the nervous system and is involved in
memory and neuronal activity. In neuronal death, the overstimulation of glutamate has been
reported. There are two forms of glutamate receptors, ionotropic and metabotropic.
Metabotropic glutamate receptors (mGluRs) have eight subtypes so far. They are divided into
subgroups (Group I: mGluR1 and mGluR5, Group II: mGluR2 and mGluR3 and Group III:
mGluR4, mGluR6, mGluR7, and mGluR8) based on cell signaling activation and sequence
homology. Metabotropic glutamate receptors are G protein-coupled receptors and are widely
spread in the central nervous system and implicated in various neurodegenerative diseases,
including Alzheimer’s disease and Parkinson and Huntington’s disease. Elevated levels of
mGluR1 have been found in the neurons of the olfactory bulb, cerebellar cortex, ventral
pallidum, globus pallidus, entopeduncular nucleus, lateral septum, magnocellular preoptic
nucleus, and thalamic nuclei.57 The widespread presence was also reported in cerebellar
Purkinje cells. Group, I mGluR expression has been observed in the substantia nigra, globus
pallidus, lateral septum, and thalamic relay nuclei.58
CREB signaling has also been reported for long-lasting changes in synaptic plasticity and
further mediates short-term memory conversion to long-term memory. CREB signaling has been
implicated in several brain pathological conditions, including cognitive and neurodegenerative
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disorders. The β-amyloid (Aβ) peptide, which plays a crucial part in Alzheimer’s disease’s
pathogenesis, also alters the hippocampal-dependent synaptic plasticity and memory and
mediates the synapse loss through CREB signaling pathway. Alteration in CREB signaling has
been associated with other cognitive disorders, including Huntington’s disease and
Rubinstein-Taybi and Coffin-Lowry syndromes suggesting an essential role of CREB signaling
in cognitive dysfunction.59
Mitochondria are essential organelles for energy metabolism and are critical for adaptation to
oxidative stress, calcium homeostasis, and cellular viability and function regulation.
Mitochondrial dysfunction in many psychiatric disorders has been reported in many
neuroimaging, GWAS, and postpartum brain analysis. Mitochondrial impairment can increase
the production of reactive oxygen species, altering the cellular functions. The accumulation of
oxidative damage in the brain results in the loss of neuronal plasticity and function. Several
GWAS studies have identified CACNA1C as one of the relevant genetic risk factors for
developing bipolar disorder and major depressive disorder.60
An explorative gene expression analysis will be performed to find the drug’s unexplained effect
on the brain. We are interested in seeing if drugs with high anticholinergic properties modulate
any genes that are already associated with neurodegeneration. We are focusing on adverse
drug reactions or how the mechanism of the ADR happens so if there is any genetic variance in
neurodegenerative genes that can cause a disease process or overexpression of any of the
pathways is linked to disease process, it is possible that drug with high anticholinergic
properties can interact with it. For this reason, we are studying Drug-Gene Interaction.
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11. EXPERIMENTAL APPROACH
11.1 CELL CULTURE EXPERIMENTS
Normal human astrocytes (Lonza, Walkersville Inc, Walkersville, MD, USA) at pass two were
seeded at a density of 5000 cells/cm2 and cultured at 80% confluence in growth media (AGM-2,
Lonza) at physiological temperature. Serum-free media (ABM-2. Lonza) was used 24 h prior to
treatment. Cell viability was assessed by trypan blue (Sigma) staining for normal human
astrocytes (NHA) treated with Diphenhydramine (Benadryl) 66ng/ml. All working solutions of
Diphenhydramine were dissolved in RNA free water (Sigma). The effects of Diphenhydramine
on MCP-1 and IL-6 proteins were observed as described below. Treatment groups included
control (untreated), and Diphenhydramine (66ng/ml) alone. Diphenhydramine was obtained
from Sigma-Aldrich. Each experiment was performed four times.

11.2 PROTEIN QUANTIFICATION AND GENE EXPRESSION
MCP-1 and IL-6 protein concentrations were measured in duplicate by immunofluorescence
detection (R&D Systems, Minneapolis, USA) and normalized to total protein content. If
Diphenhydramine induced changes in protein concentrations, gene expression was performed.
RNA (Ribonucleic acid) is isolated from the normal human astrocytes using the RNeasy mini kit
(Qiagen Inc., Valencia, USA) and converted to Complementary deoxyribonucleic acid (cDNA)
using a high capacity cDNA reverse transcription protocol (Applied Biosystems, Foster City,
USA). RNA and cDNA quality was assessed by absorbance (Thermo Scientific™ NanoDrop™
One). Real-time PCR (RT-PCR) was performed using primer and probe sets for the CACNA1C,
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CYP2D6, GCLM, GRM1, GRM2 and CREB1 and the

housekeeping gene glyceraldehyde

3-phosphate dehydrogenase (GAPDH, Taqman Gene Expression Assays, Applied Biosystems
Inc.)
11.3 STATISTICAL ANALYSIS
One-way ANOVA compared MCP-1 and IL-6 protein concentrations with Tukey correction for
multiple corrections. The gene expression was reported with relative significance (p= 0.05)
using Student’s t-test.

12. RESULTS
12.1 EFFECT OF DIPHENHYDRAMINE ON IL-6 AND MCP-1 PROTEIN PRODUCTION
Diphenhydramine produces a 10% non-significant decrease in MCP-1 protein production
(mean±SEM:

3866±49.73

pg/mg

vs

3200±327.1pg/mg, p=NS). (Fig 1) In contrast,

Diphenhydramine at doses 66ng/ml produces a statistically significant 20% decrease in IL-6
protein (mean±SEM: 85.45±3.78 pg/mg vs 68.65±1.94, pg/mg,p=0.029). (Fig 2)
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Fig 1: Effect of Diphenhydramine on MCP-1 protein production (𝙥 < 0.05 denoted by *)

Fig 2: Effect of Diphenhydramine on IL-6 protein production (𝙥 < 0.05 denoted by *)
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12.2 EFFECT OF DIPHENHYDRAMINE ON GRM-1 mRNA PRODUCTION
After observing the IL-6 protein lowering effects, we tested if diphenhydramine modulated
mRNA expression of neurocognitive genes. Diphenhydramine at doses 66 ng/ml significantly
decreased GRM1 mRNA expression (Fig 3). In contrast, diphenhydramine at doses 66 ng/ml did
not produce a significant effect on CACNA1C, CYP2D6, GCLM, GRM2, and CREB1 mRNA
expression (Fig 3).

Fig 3: Effect of Diphenhydramine on Gene mRNA production (𝙥 < 0.05 denoted by *)

13. DISCUSSION
Diphenhydramine, a first-generation antihistamine, is commonly available to treat the rash, dry
and itchy eyes, common cold, hay fever, and allergies. It is also evident from different reports
that long-term usage of drugs with high anticholinergic activity such as antihistamines can
produce cognitive impairment or decline in older adults. Anticholinergic drugs are hypothesized
to be pro-inflammatory, but in our current experimental model of normal human astrocytes,
diphenhydramine demonstrated an anti-inflammatory effect. In the present study, we observed
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diphenhydramine’s effects on MCP-1 and IL-6 protein production at physiologic drug
concentrations (66ng/ml). In this study, we found no significant reduction of diphenhydramine on
MCP-1. Animal studies suggest that MCP-1 levels were elevated in older and young
heterochronic parabionts, a young mouse whose vascular system is joined with an older
mouse.20,21 In a longitudinal analysis of an asymptomatic older adult cohort, increased MCP-1
levels were associated with longitudinal decline in verbal episodic memory.22 To add support to
their findings, Lee indicated that higher baseline MCP-1 levels are related to decreased
cognitive function over time 23

We observed a statistically significant reduction in IL-6 protein production. In the Rotterdam
Study, IL-6 was found to be associated with an increased risk of dementia. Neuroimaging
studies also demonstrated more robust associations with IL-6. In a multiethnic cohort study,
elevated serum IL-6 levels were also associated with a global measure of cognitive function. In
addition to this, higher levels were also found in Alzheimer’s disease patients’ spinal fluid.
In addition to the effects on IL-6 protein levels, diphenhydramine lowered basal GRM1 mRNA
expression.

It is a G-protein coupled receptor for glutamate. Ligand binding causes a

conformational change that triggers signaling via guanine nucleotide-binding proteins (G
proteins)

and

modulates

downstream

effectors’

activity.

Signaling

activates

a

phosphatidylinositol-calcium second messenger system. It also participates in glutamate’s
central action in the CNS, such as long-term potentiation in the hippocampus and long-term
depression in the cerebellum. After CNS injuries such as trauma or ischemia or in CNS
neurodegenerative disorders, the properties of astrocytes change, the cells become more
reactive. Stable expression of metabotropic glutamate receptors (GRM1 and GRM5) was also
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reported. Animal studies suggest that inherited ataxia can be associated with defective
expression of mGlu receptors in Purkinje cells. Ataxic transgenic mice have shown mutations of
GRM1 gene and reduced expression of mGlu receptors 24–26

In conclusion, we have observed a novel anti-inflammatory effect of diphenhydramine. Further
studies of cotreatment with IL-1b to simulate aging and characterize diphenhydramine’s effects
on different brain cell populations are warranted. Diphenhydramine prominently reduced GRM1
expression,

thus

potentially

impacting

the

glutamatergic

pathway.

The

impact

of

diphenhydramine on GRM1 mRNA expression should also be tested in additional models of
neurocognitive diseases.
The limitations of the studies include generating the hypothesis from in vitro cell culture models.
For long-term clinical outcomes, we did not consider the impact of other therapy that could
interact with diphenhydramine. We also did not consider additional pathogenic factors besides
neuroinflammation.
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14. PAROXETINE
PAXIL (paroxetine hydrochloride) is an orally administered psychotropic drug. It is the
hydrochloride salt of a phenylpiperidine compound identified chemically as (-)-trans-4R-(4'
fluorophenyl)-3S-[(3',4'-methylenedioxyphenoxy) methyl] piperidine hydrochloride hemihydrate
and has the empirical formula of C19H20FNO3•HCl•1/2H2O. The molecular weight is 374.8
(329.4 as a free base) (www.accessdata.fda.gov)
14.1 PHYSICOCHEMICAL PROPERTIES OF PAROXETINE HYDROCHLORIDE
Paroxetine hydrochloride is an odorless, off-white powder with a melting point range of 120° to
138°C and a 5.4 mg/mL solubility in water.
14.2 PHARMACOLOGY OF PAROXETINE
Paroxetine is a selective 5-HT reuptake inhibitor. Studies at clinically relevant doses in humans
have shown that paroxetine blocks serotonin’s uptake into human platelets. In vitro studies in
animals demonstrated that paroxetine is a potent and highly selective inhibitor of neuronal
serotonin reuptake and has feeble effects on norepinephrine and dopamine neuronal reuptake.
In vitro radioligand binding studies also indicated that paroxetine has some affinity for
muscarinic, alpha1-, alpha2-, beta-adrenergic-, dopamine (D2)-, 5-HT1-, 5-HT2-, and histamine
(H1)-receptors. (www.accessdata.fda.gov)
14.3 PHARMACOKINETICS OF PAROXETINE
Paroxetine is well absorbed from the gastrointestinal tract and undergoes first-pass metabolism.
Due to its lipophilic amine character, paroxetine is extensively distributed into tissues. Its plasma
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protein binding is about 95%. Paroxetine metabolism occurs within the liver and is mediated by
cytochrome

CYP2D6,

CYP3A4,

and

possibly

other

cytochrome

enzymes.

Genetic

polymorphism of CYP2D6 may alter the pharmacokinetics of paroxetine. The renal clearance of
Paroxetine is negligible. Single-dose studies reveal that the pharmacokinetics of paroxetine is
non-linear in most subjects. Also, steady-state pharmacokinetic parameters are not predictable
from single-dose data. In many subjects, daily administration of 20-50mg of paroxetine leads to
little or no disproportionality in plasma levels with dose, although this phenomenon is evident in
a few subjects. Steady-state plasma concentrations are generally achieved within 7 to 14 days.

The maximum plasma concentration of Paroxetine is 61.7ng/ml (1.67*10-4mM)
after 30 daily

doses. The terminal half-life is about one day. In elderly subjects, there is wide interindividual
variation in steady-state pharmacokinetic parameters, with statistically significantly higher
plasma concentrations and slower elimination than in younger adults. 27


15. METHOD
15.1 CELL CULTURE EXPERIMENTS
Normal human astrocytes (Lonza, Walkersville Inc, Walkersville, MD, USA) at pass two were
seeded at a density of 5000 cells/cm2 and cultured at 80% confluence in growth media (AGM-2,
Lonza) at physiological temperature. Serum-free media (ABM-2. Lonza) was used 24 h prior to
treatment. Cell viability was assessed by trypan blue (Sigma) staining for normal human

astrocytes (NHA) treated with Paroxetine (1.67*10-4mM)
. All working solutions of Paroxetine

were dissolved in RNA free water (Sigma). The effects of Paroxetine on MCP-1 protein.
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Treatment groups included control (untreated), Paroxetine (1.67*10-4
 mM) alone, IL-1B (2ng/ml)
and Paroxetine with IL-1B. Paroxetine was obtained from Sigma-Aldrich.

15.2 PROTEIN QUANTIFICATION AND GENE EXPRESSION
MCP-1 was measured in duplicate by immunofluorescence detection (R&D Systems,
Minneapolis, USA) and normalized to total protein content. If Paroxetine induced changes in
protein concentrations, gene expression was performed. RNA (Ribonucleic acid) was isolated
from the normal human astrocytes using the RNeasy mini kit (Qiagen Inc., Valencia, USA) and
converted to Complementary deoxyribonucleic acid (cDNA) using a high capacity cDNA reverse
transcription protocol (Applied Biosystems, Foster City, USA). RNA and cDNA quality was
assessed by absorbance (Thermo Scientific™ NanoDrop™ One). Real-time PCR (RT-PCR)
was performed using primer and probe sets for the CACNA1C, CYP2D6, CREB1, PPARG and
the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH, Taqman Gene
Expression Assays, Applied Biosystems Inc.)
15.3 STATISTICAL ANALYSIS
One-way ANOVA compared MCP-1 concentration with Tukey correction for multiple corrections.
The gene expression was reported with relative significance (p= 0.05) using Student’s t-test.
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16. RESULTS
16.1 EFFECT OF PAROXETINE ON IL-1B STIMULATED MCP-1 PRODUCTION
In basal conditions, Paroxetine at doses 1.67*10-4
 mM d
 id not produce any significant effects on
MCP-1 production (Fig 4). Furthermore, Paroxetine did not inhibit the induction of MCP-1 by
pro-inflammatory cytokine IL-1B (Fig 4).

( Fig 4: Effect of Paroxetine on IL-1B stimulated MCP-1 protein production (𝙥 < 0.05 denoted by *)

16.2 EFFECT OF PAROXETINE ON IL-1B STIMULATED CACNA1C AND CYP2D6 mRNA
PRODUCTION
After investigating the impact of Paroxetine on MCP-1 protein production, we tested whether
Paroxetine modulated basal or stimulated CACNA1C and CYP2D6 mRNA expression. In basal
conditions, with Paroxetine at doses 1.67*10-4
 mM, we did not see any statistically significant
41

effect. However, Paroxetine inhibits the IL-1B induced expression of CACNA1C (Fig 5) and
CYP2D6 (Fig 6).

Fig 5: Effect of Paroxetine on IL1B stimulated CACNA1C mRNA expression (𝙥 < 0.05 denoted by *)

Fig 6: Effect of Paroxetine on IL-1B stimulated CYP2D6 mRNA expression (𝙥 < 0.05 denoted by *)
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16.3 EFFECT OF PAROXETINE ON IL-1B STIMULATED CREB 1 AND PPARG mRNA
EXPRESSION
We tested whether Paroxetine at physiologic drug concentration 1.67*10-4
 mM modulated basal
or stimulated CREB1 and PPARG mRNA expression. Under basal conditions, Paroxetine did
not produce any significant effects. However, Paroxetine blunted IL-1B induction of CREB1 and
PPARG (Fig 7& Fig 8).

Fig 7: Effect of Paroxetine on IL-1B stimulated CREB 1 mRNA expression (𝙥 < 0.05 denoted by*)
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Fig 8: Effect of Paroxetine on IL-1B stimulated PPARG mRNA expression (𝙥 < 0.05 denoted by*)

17. DISCUSSION.
The prevalence rate of depression in elderly rates around 10-15% for those living in the
community. Selective Serotonin Reuptake Inhibitors, including Fluoxetine, Paroxetine,
Citalopram, Sertraline, Escitalopram is the most prescribed type of antidepressants. In 1990,
selective serotonin inhibitors (SSRIs) became the first treatment for depression, replacing the
tricyclic antidepressant (TCAs).

Many recent clinical 28,29

and preclinical studies 30–32

have

shown that the brain’s inflammatory processes are involved in depression.
In the current experimental model of normal human astrocytes, we examined the effects of
Paroxetine on IL-1B stimulated production of MCP-1 at physiologic cMax concentration
(1.67*10-4
 mM). In the current study, we observed that Paroxetine does not impact inflammation
in normal human astrocytes. Lehto et al. and Grassi-Oliveria et al. reported that depression was
associated with lower MCP-1 concentration than healthy controls.33,34 Myung et al.,2016
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reported lower MCP-1 levels in a study conducted in sixty-six Korean patients with major
depressive disorder receiving antidepressant monotherapy for six weeks (Escitalopram,
sertraline, paroxetine, fluoxetine, and mirtazapine).35 MCP-1 is known to attract peripheral
monocytes to the brain, which results in an inflammatory reaction. One case-control study
investigated the role of G-2518A polymorphism of the MCP-1 gene and found that A allele is
associated with increased psychopathology. In a Korean population, subjects with A allele were
found to have an increased risk of developing the major depressive disorder and psychotic
features compared to those with the G allele. 36
 Recently it is shown that lower serum levels of
MCP-1 predict the lack of response of antidepressants 37

We also examined the effect of Paroxetine on basal and IL-1B stimulated CACNA1C, CYP2D6,
CREB-1,

and

PPARG

mRNA expression. We observed that Paroxetine prevents

inflammation-induced mRNA expression of CACNA1C, CYP2D6, CREB-1, and PPARG.
CACNA1C encodes for the pore-forming 1C subunit of the Cav1.2 L-type calcium channel
(LTCC). CACNA1C mediates the influx of calcium ions into the cell upon membrane
polarization, plays an essential role in dendritic development, neuronal survival, synaptic
plasticity, and memory/learning.
CACNA1C has been considered a promising candidate gene associated with psychiatric
disorder.38

Polymorphisms in CACNA1C gene have been recognized by Genome-wide

association studies (GWAS) with the risk of developing schizophrenia, bipolar disorder, and
major depressive disorder.39–41

In healthy volunteers, risk-associated single nucleotide

polymorphisms in CACNA1C have predicted higher scores on depression, anxiety, negative
mood, interpersonal sensitivity. 42,43

In rodents, the pharmacological blockade of LTCCs resulted
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in antidepressants effect in learned helplessness paradigm and forced swim and tail suspension
tests. 44–46

In a large sample study conducted by Beitelshees et al, the investigators screened 46
polymorphisms within CACNA1C to investigate associations between cardiovascular disease
outcomes and treatment responses.

They discovered that rs1051375 variant status had a

significant interaction with antihypertensive treatment strategy.47
CYP2D6 is a polypeptide of 497 amino acids. Even though it accounts for only a small
percentage of total hepatic CYP450 content, its role in drug metabolism is significant. 48

CYP2D6 is a major drug-metabolizing enzyme responsible for eliminating 20% clinically used
drugs. Substrates of CYP2D6 include tricyclic antidepressants (desipramine), selective
serotonin reuptake inhibitors (paroxetine), B blockers (metoprolol), opioid analgesics (codeine)
and anti-cancer drugs (tamoxifen).49 CYP2D6 mediated drug metabolism exhibits large
inter-individual variability. Based on the urinary metabolic ratio, an individual can be classified
as ultra-rapid metabolizer (UM), normal metabolizer (NM), intermediate metabolizer (IM) and
poor metabolizer (PM) of CYP2D6.50 Paroxetine plasma levels are higher in older adults. A
double-blind, randomized trial in the elderly depressed study with Paroxetine and Nortriptyline,
conducted by Solai et al., revealed that 66 elderly depressed patients with both antidepressants
were found to have a significant correlation between pretreatment CYP2D6 activity and
steady-state plasma concentration.51
In the current experimental model in normal human astrocytes, we examined the effects of
Paroxetine on IL-1B stimulated CREB-1 and PPARG mRNA expression. We observed that
Paroxetine at a physiologic drug concentration (1.67*10-4
 mM) blunted inflammation-induced
CREB1 and PPARG mRNA expression in normal human astrocytes.
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CREB is a 43kDa transcriptional factor that belongs to the leucine zipper family and it is a final
molecular target of several signaling pathways such as c-AMP, calcium, and Ras-dependent
kinases. CREB exists in activated phosphorylated or inactive phosphorylated forms. The
phosphorylated CREB further binds to the CREB sequence on the DNA promoter region, and
the transcription process then starts.52 Nibuya reported that after chronic administration of
fluoxetine, desipramine, and mRNA CREB levels were increased in the rat hippocampus
region.53
Peroxisome proliferator-activated receptor-gamma, also known as the glitazone receptor or
NR1C3, is a type II nuclear receptor that in humans is encoded by PPARG. PPARG is a
member of the nuclear hormone receptor superfamily of ligand-activated transcription factors. It
forms a heterodimer with retinoid x receptor (RXR) to bind to specific response elements in its
target genes’ promoter region. (genecards.org). We observed that Paroxetine at a physiologic

drug concentration (1.67*10-4mM)
blunted inflammation-induced PPARG mRNA expression in

normal human astrocytes.

18. NORMAL HUMAN BRAIN MICROVASCULAR ENDOTHELIAL
CELLS
Brain microvascular endothelial cells (BMECs) are the major component of the blood-brain
barrier, limiting the passage of soluble and cellular substrates from the blood into the brain.
They have some unique features such as tight intercellular junctions that slow paracellular flux
and display high electrical resistance, the absence of fenestrae and a reduced level of pinocytic
activity, and asymmetrically localized enzymes and carrier-mediated transport systems. These
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features distinguish them from peripheral endothelial cells (Diane et al., 1995). Alterations in
blood-brain barrier properties can contribute to neurodegenerative and neuroinfectious
pathogenesis and exacerbation.

19. METHOD
19.1 CELL CULTURE EXPERIMENT
Human brain microvascular endothelial cells were grown in EBM-2 medium (Lonza,
Walkersville, MD). The cells were grown at 5% CO2, 37 C, and 95% relative humidity and when

reached 90% confluency were treated with Paroxetine (1.67*10-4mM
). Cell viability was

assessed by trypan blue (Sigma) staining for normal human brain microvascular endothelial
cells (NHBMECs) treated with Paroxetine (1.67*10-4mM). All working solutions of Paroxetine
were dissolved in RNA free water (Sigma). The effects of Paroxetine on MCP-1 protein was
observed. Treatment groups included control (untreated), Paroxetine (1.67*10- 4mM) alone,
IL-1B (2ng/ml) and Paroxetine with IL-1B. Paroxetine was obtained from Sigma-Aldrich.

19.2 PROTEIN QUANTIFICATION AND GENE EXPRESSION
MCP-1 was measured in duplicate by immunofluorescence detection (R&D Systems,
Minneapolis, USA) and normalized to total protein content. If Paroxetine induced changes in
protein concentrations, gene expression was assessed via RT-PCR. RNA (Ribonucleic acid)
was isolated from the normal human brain microvascular endothelial cells using the RNeasy
mini kit (Qiagen Inc., Valencia, USA) and converted to Complementary deoxyribonucleic acid
(cDNA) using a high capacity cDNA reverse transcription protocol (Applied Biosystems, Foster
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City, USA).

RNA and cDNA quality was assessed by absorbance (Thermo Scientific™

NanoDrop™ One). Real-time PCR (RT-PCR) was performed using primer and probe sets for
the CCL2, CXCL5, GRM1, SOD1 and CYP2D6 a
 nd the housekeeping gene glyceraldehyde
3-phosphate dehydrogenase (GAPDH, Taqman Gene Expression Assays, Applied Biosystems
Inc.)
19.3 STATISTICAL ANALYSIS
One-way ANOVA compared MCP-1 concentrations with Tukey correction for multiple
corrections. The gene expression was reported with relative significance (p= 0.05) using
Student’s t-test.

20. RESULTS
20.1 EFFECT OF PAROXETINE ON IL-1B STIMULATED MCP-1 PRODUCTION
In basal conditions, Paroxetine at 1.67*10-4
 mM in normal human brain microvascular endothelial
cells did not produce any effects on inflammation (Fig 9). Furthermore, Paroxetine did not inhibit
MCP-1 induction by IL-1B (Fig 9).

49

Fig 9: Effect of Paroxetine on IL-1B stimulated MCP-1 protein production (𝙥 < 0.05 denoted by *)

20.2 EFFECT OF PAROXETINE ON IL-1B STIMULATED CCL2 AND CXCL5 mRNA
EXPRESSION
We tested whether Paroxetine lowered basal or stimulated CCL2 and CXCL5 mRNA

expression. Paroxetine at 1.67*10-4mM
did not produce any significant effects on basal or IL-1B

treated normal human brain microvascular endothelial cells (Fig 10 & Fig 11).
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Fig 10: Effect of Paroxetine on IL-1B stimulated CCL2 mRNA expression (𝙥 < 0.05 denoted by *)

Fig 11: Effect of Paroxetine on IL-1B stimulated CXCL5 mRNA expression (𝙥 < 0.05 denoted by *)
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20.3 EFFECT OF PAROXETINE ON IL-1B STIMULATED GRM-1 AND SOD1 mRNA
EXPRESSION

In basal or IL-1B stimulated conditions, Paroxetine at doses 1.67*10-4mM
did not produce any

significant effects on GRM-1 in normal human brain microvascular endothelial cells (Fig 12).
However, basal Paroxetine treatment induced the expression of SOD-1( Fig 13).

Fig 12: Effect of Paroxetine on IL-1B stimulated GRM1 mRNA expression (𝙥 < 0.05 denoted by *)
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Fig 13: Effect of Paroxetine on IL-1B stimulated SOD1 mRNA expression (𝙥 < 0.05 denoted by *)

20.4 EFFECT OF PAROXETINE ON IL-1B STIMULATED CYP2D6 mRNA EXPRESSION
In basal conditions, Paroxetine at 1.67*10-4
 mM did not produce any significant effects on
CYP2D6 expression in normal human brain microvascular endothelial cells. However,
Paroxetine prevents IL-1B induced CYP2D6 mRNA expression in normal human brain
microvascular endothelial cells (Fig 14).
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Fig 14: Effect of Paroxetine on IL-1B stimulated CYP2D6 mRNA expression (𝙥 < 0.05 denoted by *)

21. DISCUSSION
In the current experimental model of normal human brain microvascular endothelial cells, we
examined the effects of Paroxetine on IL-1B stimulated production of MCP-1 at a physiologic

drug concentration (1.67*10-4mM).
I n the current study, we observed that Paroxetine does not

impact inflammation in normal human brain microvascular endothelial cells, similar to what we
saw with normal human astrocytes. We noted that Paroxetine prevents inflammation-induced
CYP2D6 mRNA expression similar to what we found in normal human astrocytes. Furthermore,
Paroxetine induced the expression of SOD1 i n the current experimental model of normal human
brain microvascular endothelial cells.
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SOD1 or Cu/Zn superoxide dismutase is a soluble protein that converts harmful superoxide
radicals to molecular oxygen and hydrogen peroxide. The human SOD1 gene located on
chromosome 21q22.11and codes for monomeric SOD1 polypeptide. SOD1 expression studies
still produce conflicting data about whether increased or inhibited regulation is harmful.54,55
In a study conducted, SOD1 gene expression was elevated in specific nervous systems
(brainstem and spinal cord), commonly affected by Amyotrophic Lateral Sclerosis but not in
other brain regions (cerebellum and cerebral cortex) affected during neurodegenerative
processes. 56

Further studies of cotreatment with IL-1b to simulate aging, and also to characterize the
paroxetine effects on different populations of brain cells are warranted. The impact of paroxetine
to induce the expression of SOD1 mRNA expression should also be examined in additional
models of neurocognitive diseases.
The limitations of the studies include generating the hypothesis from in-vitro cell culture models.
For long-term clinical outcomes, we did not consider the impact of other therapy that could
interact with paroxetine. We also did not consider additional pathogenic factors besides
neuroinflammation.

OVERALL CONCLUSIONS
We did not observe a shared biologically plausible pathway shared between the anticholinergic
drugs that we examined (i.e., pro-inflammatory cascade). Therefore, Comprehensive
approaches that examine the pharmacologic properties of anticholinergic drugs within the aging
brain are warranted.
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